Excess Mortality Associated With Hypopituitarism in Adults: A Meta-Analysis of Observational Studies
The DOI matches its Crossref record; 33 of the 34 references it cites were found in a registry or an index.
Abstract
Context: Several previous observational studies showed an association between hypopituitarism and excess mortality. Reports on reduction of standard mortality ratio (SMR) with GH replacement have been published recently. Objective: This meta-analysis assessed studies reporting SMR to clarify mortality risk in hypopituitary adults and also the potential benefit conferred by GH replacement. Data Sources: A literature search was performed in Medline, Embase, and Cochrane library up to March 31, 2014. Eligibility Criteria: Studies with or without GH replacement reporting SMR with 95% confidence intervals (95% CI) were included. Data Extraction and Analysis: Patient characteristics, SMR data, and treatment outcomes were independently assessed by two authors, and with consensus from third author, studies were selected for analysis. Meta-analysis was performed in all studies together, and those without and with GH replacement separately, using the statistical package metafor in R. Results: Six studies reporting a total of 19 153 hypopituiatary adults with a follow-up duration of more than 99 000 person years were analyzed. Hypopituitarism was associated with an overall excess mortality (weighted SMR, 1.99; 95% CI, 1.21–2.76) in adults. Female hypopituitary adults showed higher SMR compared with males (2.53 vs 1.71). Onset of hypopituitarism at a younger age was associated with higher SMR. GH replacement improved the mortality risk in hypopituitary adults that is comparable to the background population (SMR with GH replacement, 1.15; 95% CI, 1.05–1.24 vs SMR without GH, 2.40; 95% CI, 1.46–3.34). GH replacement conferred lower mortality benefit in hypopituitary women compared with men (SMR, 1.57; 95% CI, 1.38–1.77 vs 0.95; 95% CI, 0.85–1.06). Limitations: There was a potential selection bias of benefit of GH replacement from a post-marketing data necessitating further evidence from long-term randomized controlled trials. Conclusions: Hypopituitarism may increase premature mortality in adults. Mortality benefit from GH replacement in hypopituitarism is less pronounced in women than men.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Left untreated, anterior pituitary deficiencies are associated with decreased health and quality of life [55-59].”
From Neuroendocrine Disruptions Following Head Injury (2023) · cites this paper as [59]
In the citing paper
“undiagnosed and untreated deficiencies confer increased morbidity and mortality, which can be reversed by appropriate hormone replacement.”
From Neuroendocrine Disruptions Following Head Injury (2023) · cites this paper as [59]
In the citing paper
“However, GH replacement may reduce excess mortality from an SMR of 2.40 (95% CI 1.46-3.34) to 1.99 (95% CI 1.21-2.76),especially in men (60).”
From Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline (2016) · cites this paper as [60]
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Conducting Meta-Analyses in R with the metafor Package
Viechtbauer, W. (2010) · Journal of Statistical Software · doi:10.18637/jss.v036.i03 · Cited by 20,464 · cited 1×
“Quality assessment of the included articles was performed using the Newcastle Ottawa Scale (NOS) for cohort studies (17), modified for this meta-analysis.”
Method(2014) · Medical Entomology and Zoology · Cited by 17,633
Premature mortality due to cardiovascular disease in hypopituitarism
Rosén, T., & Bengtsson, B.-Å. (1990) · The Lancet · doi:10.1016/0140-6736(90)91812-o · Cited by 1,402 · cited 1×
“The increased risk of premature mortality associated with hypopituitarism was first identified by Rosén and Bengtsson (5) more than two decades ago.”
BackgroundThe prevalence of pituitary adenomas: A systematic review
Ezzat, S., Asa, S. L., Couldwell, W. T., Barr, C. E., Dodge, W. E., Vance, M. L., & McCutcheon, I. E. (2004) · Cancer · doi:10.1002/cncr.20412 · Cited by 1,345
Salomon, F., Cuneo, R. C., Hesp, R., & Sönksen, P. H. (1989) · New England Journal of Medicine · doi:10.1056/nejm198912283212605 · Cited by 1,326 · cited 1×
“3 Median: 53 M; 51F N/A 56 (31) 119 (69) Bülow et al, 1997 (7) 344 62.”
Association between premature mortality and hypopituitarism
Tomlinson, J., Holden, N., Hills, R., Wheatley, K., Clayton, R., Bates, A., Sheppard, M., & Stewart, P. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04006-x · Cited by 1,006
Self-citationBENEFICIAL EFFECTS OF GROWTH HORMONE TREATMENT IN GH-DEFICIENT ADULTS
Jørgensen, J. O. L., Thuesen, L., Ingemann-Hansen, T., Pedersen, S. A., Jørgensen, I., Skakkebaek, N. E., & Christiansen, J. S. (1989) · The Lancet · doi:10.1016/s0140-6736(89)92328-3 · Cited by 890
Increased cerebrovascular mortality in patients with hypopituitarism
Bülow, B., Hagmar, L., Mikoczy, Z., Nordström, C., & Erfurth, E. M. (1997) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1997.d01-1749.x · Cited by 542
Cited by
Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline
Fleseriu, M., Hashim, I. A., Karavitaki, N., Melmed, S., Murad, M. H., Salvatori, R., & Samuels, M. H. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2118 · Cited by 945
Systemic Complications of Acromegaly and the Impact of the Current Treatment Landscape: An Update
Gadelha, M. R., Kasuki, L., Lim, D. S. T., & Fleseriu, M. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00115 · Cited by 363
Growth hormone — past, present and future
Ranke, M. B., & Wit, J. M. (2018) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2018.22 · Cited by 346
Diagnosis and Management of Pituitary Adenomas: A Review
Tritos, N. A., & Miller, K. K. (2023) · JAMA · doi:10.1001/jama.2023.5444 · Cited by 331
Yuen, K. C. J., Biller, B. M. K., Radovick, S., Carmichael, J. D., Jasim, S., Pantalone, K. M., & Hoffman, A. R. (2019) · Endocrine Practice · doi:10.4158/gl-2019-0405 · Cited by 298
Acromegaly: pathogenesis, diagnosis, and management
Fleseriu, M., Langlois, F., Lim, D. S. T., Varlamov, E. V., & Melmed, S. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00244-3 · Cited by 279
Treating the Side Effects of Exogenous Glucocorticoids; Can We Separate the Good From the Bad?
Pofi, R., Caratti, G., Ray, D. W., & Tomlinson, J. W. (2023) · Endocrine Reviews · doi:10.1210/endrev/bnad016 · Cited by 209
Newman, C. B., Blaha, M. J., Boord, J. B., Cariou, B., Chait, A., Fein, H. G., Ginsberg, H. N., Goldberg, I. J., Murad, M. H., Subramanian, S., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa674 · Cited by 172
Fleseriu, M., Christ‐Crain, M., Langlois, F., Gadelha, M. R., & Melmed, S. K. (2024) · The Lancet · doi:10.1016/s0140-6736(24)00342-8 · Cited by 142
Mortality in adults with hypopituitarism: a systematic review and meta-analysis
Jasim, S., Alahdab, F., Ahmed, A. T., Tamhane, S., Prokop, L. J., Nippoldt, T. B., & Murad, M. H. (2017) · Endocrine · doi:10.1007/s12020-016-1159-3 · Cited by 112
Olsson, D. S., Nilsson, A. G., Bryngelsson, I.-L., Trimpou, P., Johannsson, G., & Andersson, E. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1475 · Cited by 110
Esposito, D., Ragnarsson, O., Granfeldt, D., Marlow, T., Johannsson, G., & Olsson, D. S. (2018) · European Journal of Endocrinology · doi:10.1530/eje-18-0015 · Cited by 105
Increased mortality risk in patients with primary and secondary adrenal insufficiency
Ngaosuwan, K., Johnston, D. G., Godsland, I. F., Cox, J., Majeed, A., Quint, J. K., Oliver, N., & Robinson, S. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab096 · Cited by 77
Hammarstrand, C., Ragnarsson, O., Hallén, T., Andersson, E., Skoglund, T., Nilsson, A. G., Johannsson, G., & Olsson, D. S. (2017) · European Journal of Endocrinology · doi:10.1530/eje-17-0340 · Cited by 70
DIAGNOSIS OF ENDOCRINE DISEASE: Expanding the cause of hypopituitarism
Pekic, S., & Popovic, V. (2017) · European Journal of Endocrinology · doi:10.1530/eje-16-1065 · Cited by 69
Growth Hormone Research Society perspective on biomarkers of GH action in children and adults
Johannsson, G., Bidlingmaier, M., Biller, B. M. K., Boguszewski, M., Casanueva, F. F., Chanson, P., Clayton, P. E., Choong, C. S., Clemmons, D., Dattani, M., et al. (2018) · Endocrine Connections · doi:10.1530/ec-18-0047 · Cited by 60
Covert actions of growth hormone: fibrosis, cardiovascular diseases and cancer
Kopchick, J. J., Basu, R., Berryman, D. E., Jørgensen, J. O. L., Johannsson, G., & Puri, V. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00702-6 · Cited by 61
A proposed clinical classification for pituitary neoplasms to guide therapy and prognosis
Ho, K. K. Y., Fleseriu, M., Wass, J. A. H., Katznelson, L. J., Raverot, G., Little, A. S., Castano, J. P., Reincke, M., Lopes, M. B. S., Kaiser, U. B., et al. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(23)00382-0 · Cited by 61
Jørgensen, J. O. L., & Juul, A. (2018) · European Journal of Endocrinology · doi:10.1530/eje-18-0306 · Cited by 60
Cerbone, M., Güemes, M., Wade, A., Improda, N., & Dattani, M. (2020) · EClinicalMedicine · doi:10.1016/j.eclinm.2019.11.017 · Cited by 42
“A recent metanalysis in adults with hypopituitarism due to various aetiologies has shown that hypopituitarism tends to increase premature mortality in affected individuals, and that GH replacement seems to improve the overall mortality [37].”
BackgroundLife expectancy in patients with pituitary adenoma receiving growth hormone replacement
Olsson, D. S., Trimpou, P., Hallén, T., Bryngelsson, I.-L., Andersson, E., Skoglund, T., Bengtsson, B.-Å., Johannsson, G., & Nilsson, A. G. (2017) · European Journal of Endocrinology · doi:10.1530/eje-16-0450 · Cited by 45
Olsson, D. S., Bryngelsson, I., & Ragnarsson, Ó. (2016) · European Journal of Endocrinology · doi:10.1530/eje-16-0173 · Cited by 49
Johannsson, G., Touraine, P. A., Feldt‐Rasmussen, U., Pico, A. M., Vila, G., Mattsson, A. F., Carlsson, M. O., Korbonits, M., van Beek, A. P., Wajnrajch, M. P., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac199 · Cited by 53
Losa, M., Castellino, L., Pagnano, A., Rossini, A., Mortini, P., & Lanzi, R. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa089 · Cited by 42
Kim, J. H., Chae, H. W., Chin, S. O., Ku, C. R., Park, K. H., Lim, D. J., Kim, K. J., Lim, J. S., Kim, G., Choi, Y. M., et al. (2020) · Endocrinology and Metabolism · doi:10.3803/enm.2020.35.2.272 · Cited by 52
“A meta-analysis also found that GH replacement reduced the mortality rate among male patients with hypopituitarism [84], and a domestic study reported a reduction in markers of inflammation through GH replacement [70].”
BackgroundJohannsson, G., & Ragnarsson, Ó. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13382 · Cited by 46
Metabolic Syndrome in Hypopituitarism
Miljić, D., & POPOVIC, V. M. (2018) · Frontiers of hormone research · doi:10.1159/000485997 · Cited by 43
Adult growth hormone deficiency: clinical advances and approaches to improve adherence
Yuen, K. C. J., Llahana, S., & Miller, B. S. (2019) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2019.1689119 · Cited by 41
Sensitivity and specificity of the macimorelin test for diagnosis of AGHD
Garcia, J. M., Biller, B. M. K., Korbonits, M., POPOVIC, V. M., Luger, A., Strasburger, C. J., Chanson, P., Swerdloff, R. S., Wang, C., Fleming, R. R., et al. (2020) · Endocrine Connections · doi:10.1530/ec-20-0491 · Cited by 39
“Findings from recent studies suggest that hypopituitarism is associated with excess mortality (3, 4, 5, 6, 7), in part due to AGHD (8, 9).”
BackgroundYuen, K. C. J., Mattsson, A. F., Burman, P., Erfurth, E.-M., Camacho-Hubner, C., Fox, J. L., Verhelst, J., Geffner, M. E., & Abs, R. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-01542 · Cited by 33
“(17), reported beneficial effects favoring GH re-”
Mechanisms of ageing: growth hormone, dietary restriction, and metformin
Khan, J., Pernicova, I., Nisar, K., & Korbonits, M. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(23)00001-3 · Cited by 35
A Comprehensive Review of Empty Sella and Empty Sella Syndrome
Lundholm, M. D., & Yogi-Morren, D. (2024) · Endocrine Practice · doi:10.1016/j.eprac.2024.03.004 · Cited by 34
Yu, Q., Qiu, Y., Li, C., Wang, Z., Cao, B.-W., Huang, H.-X., Ni, Y.-H., Chen, L., & Sun, J. (2020) · Pituitary · doi:10.1007/s11102-020-01032-4 · Cited by 32
“Though generally benign, pituitary adenomas still increase mortality among patients and impose a health and financial burden worldwide [4].”
BackgroundFang, Y., Wang, H., Feng, M., Zhang, W., Cao, L., Ding, C., Chen, H., Wei, L., Mu, S., Pei, Z., et al. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.748725 · Cited by 29
The Oxytocin System and Implications for Oxytocin Deficiency in Hypothalamic-Pituitary Disease
Aulinas, A., & Lawson, E. A. (2025) · Endocrine Reviews · doi:10.1210/endrev/bnaf008 · Cited by 35
Update on GH therapy in adults
Boguszewski, C. L. (2017) · F1000Research · doi:10.12688/f1000research.12057.1 · Cited by 29
Traumatic Brain Injury: At the Crossroads of Neuropathology and Common Metabolic Endocrinopathies
Li, M., & Sirko, S. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7030059 · Cited by 31
“In general, HP is a relatively rare condition, affecting 46 per 100,000 patients [34], and is mostly caused by adenomas or other tumorous lesions associated with higher mortality [35].”
BackgroundRadiotherapy as a tool for the treatment of Cushing’s disease
Castinetti, F., Brue, T. C., & Ragnarsson, Ó. (2019) · European Journal of Endocrinology · doi:10.1530/eje-19-0092 · Cited by 33
Is there a role for early chemotherapy in the management of pituitary adenomas?
Lin, A. L., Sum, M., & DeAngelis, L. M. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now059 · Cited by 31
Ebrahimi, F., Kutz, A., Wagner, U., Illigens, B. M. W., Siepmann, T., Schüetz, P., Christ‐Crain, M., Müeller, B., & Christ, E. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa517 · Cited by 28
Sheehan syndrome: a current approach to a dormant disease
Karaca, Z., & Keleştimur, F. (2025) · Pituitary · doi:10.1007/s11102-024-01481-1 · Cited by 33
“The mortality rate is increased in patients with hypopituita-rism which is caused by increased cardiovascular diseases, strokes and malignancy [50, 51].”
Sheehan syndrome: Cardiovascular and metabolic comorbidities
Laway, B. A., & Baba, M. S. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1086731 · Cited by 30
Neuroendocrine Disruptions Following Head Injury
Wexler, T. L. (2023) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-023-01263-5 · Cited by 23
Garmes, H. M., Boguszewski, C. L., Miranda, P. A. C., Martins, M. R. A., Correa‐Silva, S. R., Abucham, J., Musolino, N. R. D. C., Vilar, L., Portari, L. H. C., Gadelha, M. R., et al. (2021) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-3997000000335 · Cited by 31
“GH therapy does not change the prevalence of metabolic syndrome over time but, intriguingly, has been associated with reduction or even normalization of mortality in AGHD (6,32,33,112,113).”
BackgroundInfluentialOlsson, D. S., Bryngelsson, I., & Ragnarsson, Ó. (2016) · Pituitary · doi:10.1007/s11102-016-0764-8 · Cited by 24
“Furthermore, women with pituitary insufficiency have frequently been found to have an increased mortality compared to men [1, 3, 8].”
BackgroundResultOxytocin therapy in hypopituitarism: Challenges and opportunities
Bhargava, R., Daughters, K., & Rees, A. (2018) · Clinical Endocrinology · doi:10.1111/cen.13909 · Cited by 25
Hamblin, R., Tsermoulas, G., & Karavitaki, N. (2021) · La Presse Médicale · doi:10.1016/j.lpm.2021.104078 · Cited by 22
He, X., & Barkan, A. L. (2020) · Pituitary · doi:10.1007/s11102-020-01031-5 · Cited by 25
Yedinak, C. G., Cetas, I., Ozpinar, A., McCartney, S., Dog⫧an, A., & Fleseriu, M. (2016) · Endocrine · doi:10.1007/s12020-016-1042-2 · Cited by 20
The heart in growth hormone (GH) deficiency and the cardiovascular effects of GH
Chanson, P. (2020) · Annales d Endocrinologie · doi:10.1016/j.ando.2020.03.005 · Cited by 22
A 2024 Update on Growth Hormone Deficiency Syndrome in Adults: From Guidelines to Real Life
Aversa, L. S., Cuboni, D., Grottoli, S., Ghigo, E., & Gasco, V. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13206079 · Cited by 25
“Additionally, prior research has suggested that hypopituitarism is associated with increased mortality [13,18], partly attributable to GHD [101].”
BackgroundMetabolic syndrome and its components in adult hypopituitary patients
Abe, S. Y., dos Santos, K. S., Barbosa, B. F. B., Biondo, C., Takito, D., Hayashi, S. K., Amarilla, V. G. V., Ulbrich, A. Z., & Boguszewski, C. L. (2020) · Pituitary · doi:10.1007/s11102-020-01048-w · Cited by 22
Singh, H., Afroze, M., Shafi, N., Bhat, J. A., Kawa, I. A., Laway, B. A., Bhat, S. A., Bhat, M. H., Zargar, A. H., Hussain, A., et al. (2021) · Pituitary · doi:10.1007/s11102-021-01174-z · Cited by 19
Long-term hepatic and cardiac health in patients diagnosed with Sheehan’s syndrome
Das, L., Sahoo, J., Dahiya, N., Taneja, S., Bhadada, S. K., Bhat, M. H., Singh, P., Suri, V., Laway, B. A., & Dutta, P. R. (2022) · Pituitary · doi:10.1007/s11102-022-01282-4 · Cited by 17
“The premature and excess mortality in hypopituitarism is more common in young females [8, 21], and patients with SS qualify for both criteria.”
BackgroundIncidence of malignant tumours in patients with a non-functioning pituitary adenoma
Olsson, D. S., Hammarstrand, C., Bryngelsson, I., Nilsson, A. G., Andersson, E., Johannsson, G., & Ragnarsson, Ó. (2017) · Endocrine Related Cancer · doi:10.1530/erc-16-0518 · Cited by 16
Radiotherapy and Mortality in Pituitary Adenomas
González‐Virla, B., Vargas‐Ortega, G., & Romero‐Gameros, C. A. (2023) · Archives of Medical Research · doi:10.1016/j.arcmed.2023.102900 · Cited by 17
Bonert, V. S., & Melmed, S. K. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804169-7.00004-0 · Cited by 23
Adult Growth Hormone Deficiency: Diagnostic and Treatment Journeys From the Patients’ Perspective
Hoffman, A. R., Mathison, T., Andrews, D., Murray, K., Kelepouris, N., & Fleseriu, M. (2022) · Journal of the Endocrine Society · doi:10.1210/jendso/bvac077 · Cited by 16
“Clinical manifestations of AGHD include cardiovascular disease, abdominal obesity, reduced psychological wellbeing, and quality of life, and overall effects on health that, for some patients, could lead to reduced life expectancy [4, 8-13].”
BackgroundFierro, G., & Hoffman, A. R. (2020) · Growth Hormone & IGF Research · doi:10.1016/j.ghir.2020.101316 · Cited by 12
Boguszewski, C. L. (2023) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2023.101817 · Cited by 14
Garmes, H. M. (2024) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-023-09872-8 · Cited by 16
“Based on observational studies, two meta-analyses confirm that mortality rates are increased in patients with PH, especially when the diagnosis is made in younger patients and in women [5, 6].”
Bioletto, F., Sibilla, M., Gasco, V., Ghigo, E., & Grottoli, S. (2024) · Journal of Endocrinological Investigation · doi:10.1007/s40618-024-02356-9 · Cited by 14
“Given that patients with NFPA frequently have pituitary insufficiency at least to some degree, and that hypopi-tuitarism of various etiologies is associated with increased mortality [20], a slightly increased mortality risk in patients with NFPA might be expected.”
BackgroundResultInfluentialAn Overview of Cardiovascular Risk in Pituitary Disorders
Ntali, G., Markussis, V., & Chrisoulidou, A. (2024) · Medicina · doi:10.3390/medicina60081241 · Cited by 13
“However, the development of CV diseases constitutes the main cause of mortality in these patients [1–12].”
BackgroundInfluentialGrowth hormone replacement in adults: Real-world data from two large studies in US and Europe
Weber, M. M., Gordon, M. B., Höybye, C., Jørgensen, J. O. L., Puras, G., Popović-Brkić, V., Molitch, M. E., Ostrow, V., Holot, N., Pietropoli, A., et al. (2019) · Growth Hormone & IGF Research · doi:10.1016/j.ghir.2019.09.002 · Cited by 13
Pituitary adenomas: biology, nomenclature and clinical classification
Ho, K. K. Y., & Melmed, S. K. (2025) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-025-09944-x · Cited by 14
“Hypopituitarism increases mortality risk in patients harbouring pituitary adenomas [48].”
Guignat, L., Proust-Lemoine, E., Reznik, Y., & Zénaty, D. (2017) · Annales d Endocrinologie · doi:10.1016/j.ando.2017.10.009 · Cited by 11
Abe, I., Takeshita, K., Nagata, M., Fujita, Y., Ochi, K., Koga, M., Kudo, T., Shimada, H., Abe, M., Mukoubara, S., et al. (2023) · Medicine · doi:10.1097/md.0000000000034730 · Cited by 11
Reflex and reflective testing strategies for early detection of pituitary dysfunction
Elnenaei, M. O., Minney, D. C., Clarke, D. B., Kumar‐Misir, A., & Imran, S. A. (2018) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2018.02.014 · Cited by 10
Androgen deficiency in hypopituitary women: its consequences and management
Espósito, D., Tivesten, Å., Olivius, C., Ragnarsson, Ó., & Johannsson, G. (2024) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-024-09873-1 · Cited by 9
“Women with hypopituitarism have more marked morbidity and mortality than men [4, 5].”
BackgroundHealthcare cost and survival in patients with non-functioning pituitary adenoma
Olsson, D. S., Svensson, M., Labori, F., Geer, A. D., & Johannsson, G. (2023) · European Journal of Endocrinology · doi:10.1093/ejendo/lvad057 · Cited by 10
Hypopituitarism and Cardiovascular Risk
Kraljević, I., Solak, M., Mandić, A., Kozamernik, K. M., Raičević, M., Divanović, A., Kovačević, Z., & Muzurović, E. M. (2025) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/10742484251332398 · Cited by 10
“36 In another metaanalysis (n = 19,153 hypo-pituitary adults, six studies, follow-up of >99,000 person-years), hypopituitarism was associated with an overall increased mortality (weighted SMR 1.99) in adults, and earlier onset of hypopituitarism was associated with a higher SMR. 36 Furthermore,…”
InfluentialReduced CV risk with long-term GH replacement in AGHD: data from two large observational studies
Höybye, C., Biller, B. M. K., Ferran, J.-M., Gordon, M. B., Kelepouris, N., Nedjatian, N., Olsen, A. H., & Weber, M. M. (2022) · Endocrine Connections · doi:10.1530/ec-22-0267 · Cited by 9
“…patients with AGHD typically have unfavourable alterations in body composition, a decreased capacity for exercise, impaired quality of life, an adverse lipid profile and an increased risk for cardiovascular (CV)- associated disease, diabetes and metabolic syndrome vs healthy adults (4, 5, 6, 7).”
Why do patients with hypopituitarism still present an increased mortality?
Ebrahimi, F., & Christ, E. (2023) · Annales d Endocrinologie · doi:10.1016/j.ando.2023.02.002 · Cited by 8
Shimatsu, A., Ishii, H., Nishinaga, H., Murai, O., & Chihara, K. (2017) · Endocrine Journal · doi:10.1507/endocrj.ej16-0604 · Cited by 8
Adult growth hormone deficiency in CEE region: Heterogeneity of the patient pathway
Shimon, I., Badiu, C., Bossowski, A. T., Doknić, M., Dzīvīte-Krišāne, I., Hána, V., Kollerová, J., Natchev, Е., Pfeifer, M., Szücs, N., et al. (2019) · Growth Hormone & IGF Research · doi:10.1016/j.ghir.2019.06.001 · Cited by 10
Prevalence and risk of complications in untreated patients with adult growth hormone deficiency
Fukuoka, H., Endo, T., Tsuboi, S., & Fujio, S. (2025) · Pituitary · doi:10.1007/s11102-025-01500-9 · Cited by 10
“Metabolic abnormalities are associated with increased mortality, mainly due to cardiovascular events, which can lead to a shortened life expectancy [ 9 –11].”
Yuen, K. C. J., Birkegård, A. C., Blevins, L. S., Clemmons, D. R., Hoffman, A. R., Kelepouris, N., Kerr, J. M., Tarp, J. M., & Fleseriu, M. (2022) · International Journal of Endocrinology · doi:10.1155/2022/7853786 · Cited by 8
“Furthermore, it is likely that AGHD contributes to increased cardiovascular (CV)morbidity andmortality compared with the general population, especially in patients with panhypopituitarism [5, 6].”
BackgroundGrowth hormone replacement in adults with cured acromegaly: Efficacy and safety
Tritos, N. A. (2023) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2023.101790 · Cited by 6
Management of Dyslipidemia in Endocrine Diseases
Tannock, L. R. (2022) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2022.02.003 · Cited by 8
Stem cell therapy and its potential role in pituitary disorders
Lara-Velazquez, M. A., Akinduro, O. O., REIMER, R. R., Woodmansee, W. W., & Quiñones‐Hinojosa, A. (2017) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000346 · Cited by 7
Clinical manifestations and treatment of hypopituitarism due to traumatic brain injury
Zhang, C. D., & Ioachimescu, A. G. (2025) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2025.101996 · Cited by 5
Krivosheeva, Y. G., & Ilovayskaya, I. (2021) · Almanac of Clinical Medicine · doi:10.18786/2072-0505-2021-49-047 · Cited by 5
Treating Hypopituitarism in the Over 65s: Review of Clinical Studies
Paragliola, R. M., Locantore, P., Corsello, S. M., & Salvatori, R. (2023) · Clinical Interventions in Aging · doi:10.2147/cia.s370782 · Cited by 6
Hypopituitarism and Growth Hormone Deficiency in Adults
Llahana, S., Marland, A., Pantovic, M., & POPOVIC, V. M. (2019) · Springer eBooks · doi:10.1007/978-3-319-99817-6_25 · Cited by 6
Current aspects of diagnosis and treatment of adult GH-deficiency
Lutsenko, A. S., Nagaeva, E. V., Belaya, Z. E., Chukhacheva, O. S., Zenkova, T. S., & Mel'nichenko, G. A. (2019) · Problems of Endocrinology · doi:10.14341/probl10322 · Cited by 7
“, стандартизованный показатель смертности составил 2,40 [95% ДИ 1,46–3,34] у пациентов с СТГ дефицитом без лечения и 1,15 [95% ДИ 1,05–1,24] у пациентов, получающих соматотропин [103].”
Hypertension in growth hormone excess and deficiency
Mihai, G., & Korbonits, M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-96120-2.00017-0 · Cited by 6
Diagnosing and treating the elderly individual with hypopituitarism
Corsello, A., Paragliola, R. M., & Salvatori, R. (2023) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-023-09870-w · Cited by 5
“Hypopituitarism has been associated with an increase in mortality, and the impact of some hormonal replacement therapies, including growth hormone (GH), is still unclear [2].”
Clinical Management of Postoperative Growth Hormone Deficiency in Hypothalamic-Pituitary Tumors
Iglesias, P. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13154307 · Cited by 4
“A meta-analysis showed that the standardized mortality rate in patients treated with rhGH was 1.15 [95% CI: 1.05–1.24] compared to 2.40 [95% CI: 1.46–3.34] in patients not treated with rhGH [46].”
MethodInfluentialHypopituitarism—needs modern individualized treatment
Olsson, D. S., & Bengtsson, B. (2016) · Endocrine · doi:10.1007/s12020-016-1211-3 · Cited by 4
Zaliunas, B. R., Pileckaitė, E., Duseikaitė, M., Makštienė, J., Poškienė, L., Rovīte, V., Wu, S., Tamašauskas, A., & Liutkevičienė, R. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1657520 · Cited by 3
“In addition, macroadenomas can also present with headaches or hypopituitarism due to the mass effect (3).”
Laway, B. A., Arun Viswanath, S., Baba, M. S., Tramboo, N. A., Shah, Z. A., Lone, A. A., & Hafeez, I. (2024) · The Indian Journal of Medical Research · doi:10.25259/ijmr_622_22 · Cited by 3
“Hypopituitarism with varied and non-specific symptomology can add to impaired quality of life in the elderly 26 .”
BackgroundPituitary Dysfunction as a Cause of Cardiovascular Disease
Gogakos, A. I., Gogakos, T., Kita, M. D., & Efstathiadou, Z. A. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612824999201105165351 · Cited by 3
Wu, J., Wu, X., Yang, L., Xie, S., Tang, B., Tong, Z., Wu, B., Yang, Y., Ding, H., Bao, Y., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.840572 · Cited by 6
Gao, J., Wang, Y., Zhang, A., Pang, H., & Wang, F. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1353392 · Cited by 3
A Non-Secreting Pituitary Adenoma That Changed to a Prolactinoma
Santiago-Vazquez, C., Palacios-Paíno, N., & Cordido, F. (2024) · Clinics and Practice · doi:10.3390/clinpract14040106 · Cited by 2
“People with hypopituitarism, including GH deficiency, due to PA have an approximately two-fold increase in mortality compared with the general population [5,6].”
BackgroundMilioto, A., Espósito, D., Johannsson, G., & Ragnarsson, Ó. (2026) · Pituitary · doi:10.1007/s11102-026-01646-0 · Cited by 3
“A meta-analysis published in 2015 pooled mortality data from over 19,000 patients with hypopituitarism, regardless of whether GHD was diagnosed or not [79].”
Herman-Bonert, V. S., & Melmed, S. K. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-99899-4.00023-8 · Cited by 7
Is GH Replacement for Adult GH Deficiency Safe?
Melmed, S. K. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac307 · Cited by 2
“Adult GH replacement administered appropriately at physiologic doses to patients with rigorously proven pituitary dysfunction may improve lean body mass, reverse central obesity and associated metabolic dysfunction, improve or arrest osteoporosis, enhance quality of life (3), and possibly reverse adverse mortality rat…”
BackgroundACTH-dependent Cushing's syndrome
Fernandes, S., Varlamov, E. V., & Fleseriu, M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-96120-2.00011-x · Cited by 2
Shine, B. S. F., James, T. J., & Adler, A. (2019) · BMJ Open · doi:10.1136/bmjopen-2019-029369 · Cited by 2
“Identifying people with undetected pituitary disease is likely to improve both quality of life and length of life as people with untreated pituitary disease have higher mortality rates than patients with treated hypothalamic or pituitary disease, even when the TSH is normal and/or they do not have symptoms.(5) Because…”
Background
Metadata
- Authors
- Pappachan, J. M., Raskauskiene, D., Kutty, V. R., & Clayton, R. N.
- Affiliations
- Walsall Manor Hospital (GB)
- Sree Chitra Thirunal Institute for Medical Sciences and Technology (IN)
- University Hospitals of North Midlands NHS Trust (GB)
- Corresponding author
- Pappachan, Joseph M.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2015-04-01
- Volume
- 100
- Issue
- 4
- Pages
- 1405-1411
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2097556482
- Semantic Scholar
- 00593eb004f6fde4fa72eed78a1247a323891575
- Cited by
- 138
- References
- 34
- Citations by year
- 2026: 6 · 2025: 18 · 2024: 18 · 2023: 19 · 2022: 16 · 2021: 9 · 2020: 13 · 2019: 9 · 2018: 10 · 2017: 10 · 2016: 8 · 2015: 1
- FWCI
- 1.46
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Keywords
- excess mortality, standardized mortality ratio, growth hormone replacement therapy, premature mortality, sex differences, post-marketing surveillance
- MeSH terms
- Adult, Female, Humans, Hypopituitarism, Male, Middle Aged, Human Growth Hormone, Hormone Replacement Therapy, Observational Studies as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.